PUBLISHER: Lucintel | PRODUCT CODE: 1417485
PUBLISHER: Lucintel | PRODUCT CODE: 1417485
HIV Diagnostic Trends and Forecast
The future of the global HIV diagnostic market looks promising with opportunities in the diagnostic laboratories and hospital markets. The global HIV diagnostic market is expected to reach an estimated $7.6 billion by 2030 with a CAGR of 10.1% from 2024 to 2030. The major drivers for this market are growing number of blood donations and transfusions, advantages provided by point-of-care equipment & supplies, and increasing HIV-related government initiatives.
A more than 150-page report is developed to help in your business decisions.
HIV Diagnostic by Segment
The study includes a forecast for the global HIV diagnostic by product, test type, end use, and region.
List of HIV Diagnostic Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies HIV diagnostic companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the HIV diagnostic companies profiled in this report include-
HIV Diagnostic Market Insights
Lucintel forecasts that antibody test is expected to witness the highest growth over the forecast period.
North America will remain the largest region over the forecast period due to growing healthcare infrastructure and the high prevalence of HIV infection that have resulted in a greater need for efficient healthcare services.
Features of the Global HIV Diagnostic Market
Market Size Estimates: HIV Diagnostic market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: HIV Diagnostic market size by product, test type, end use, and region in terms of value ($B).
Regional Analysis: HIV Diagnostic market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different product, test type, end use, and regions for the HIV diagnostic market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the HIV diagnostic market.
Analysis of competitive intensity of the industry based on Porter's Five Forces model.
FAQ
Q1. What is the HIV diagnostic market size?
Answer: The global HIV diagnostic market is expected to reach an estimated $7.6 billion by 2030.
Q2. What is the growth forecast for HIV diagnostic market?
Answer: The global HIV diagnostic market is expected to grow with a CAGR of 10.1% from 2024 to 2030.
Q3. What are the major drivers influencing the growth of the HIV diagnostic market?
Answer: The major drivers for this market are growing number of blood donations and transfusions, advantages provided by point-of-care equipment & supplies, and increasing HIV-related government initiatives.
Q4. What are the major segments for HIV diagnostic market?
Answer: The future of the global HIV diagnostic market looks promising with opportunities in the diagnostic laboratories and hospital markets.
Q5. Who are the key HIV diagnostic market companies?
Answer: Some of the key HIV diagnostic companies are as follows.
Q6. Which HIV diagnostic market segment will be the largest in future?
Answer: Lucintel forecasts that antibody test is expected to witness the highest growth over the forecast period.
Q7. In HIV diagnostic market, which region is expected to be the largest in next 5 years?
Answer: North America will remain the largest region over the forecast period due to growing healthcare infrastructure and the high prevalence of HIV infection that have resulted in a greater need for efficient healthcare services.
Q.8 Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.